4/A: Taysha Gene Therapies CFO Amends Filing to Disclose Previously Omitted Stock Option Award

Kamran Alam, CFO of Taysha Gene Therapies, files an amended Form 4 to report a previously omitted stock option award granted in February 2023 that vested on May 31, 2023.

Summary

• Kamran Alam, the Chief Financial Officer of Taysha Gene Therapies, Inc., filed an amended Form 4 with the SEC.
• The amendment corrects an omission in the original filing regarding a stock option award.
• The stock option, granting the right to buy 12,462 shares of common stock at $1.18 per share, was awarded on February 2, 2023, as incentive compensation for 2022 performance.
• The Compensation Committee certified the achievement of a performance goal on May 31, 2023, upon which the shares underlying the option vested.
• The CFO directly owns 12,462 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a routine correction of a regulatory filing. The amendment itself doesn't indicate positive or negative performance, but rather ensures accurate reporting.

Negatives

• The original Form 4 filing was incomplete, requiring an amendment.

Risks

• Failure to accurately report transactions in a timely manner can lead to regulatory scrutiny.

Industry Context

Reporting of beneficial ownership is a standard practice for company insiders to ensure transparency and prevent insider trading. This filing relates to equity-based compensation, a common practice in the biotech industry to incentivize executives.

Key Dates

Keywords

Form 4, Amendment, Stock Option, Taysha Gene Therapies, Kamran Alam, CFO, Beneficial Ownership, Incentive Compensation